Shares of Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company.
STVN has been the subject of several research reports. Citigroup reduced their price objective on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. KeyCorp cut their target price on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Weiss Ratings downgraded Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday. Wall Street Zen lowered Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Morgan Stanley dropped their price target on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Friday, March 6th.
Read Our Latest Stock Analysis on Stevanato Group
Institutional Inflows and Outflows
Stevanato Group Trading Up 2.7%
Shares of NYSE:STVN opened at €15.03 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.26 and a current ratio of 1.76. The stock has a market capitalization of $4.55 billion, a price-to-earnings ratio of 25.92, a PEG ratio of 1.34 and a beta of 0.57. Stevanato Group has a 1-year low of €13.91 and a 1-year high of €28.00. The company has a 50 day moving average price of €17.06 and a 200 day moving average price of €21.40.
About Stevanato Group
Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.
In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.
See Also
- Five stocks we like better than Stevanato Group
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- A personal warning from Martin Weiss (Please read)
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
